Stereotaxis (NYSE:STXS) has announced that it has received European CE Mark approval for its MAGIC ablation catheter, designed to perform cardiac ablation procedures aimed at treating heart arrhythmia.
According to Stereotaxis, this approval is a significant milestone for the company and the community of physicians pioneering robotics in electrophysiology. The MAGiC catheter was developed based on nearly two decades of insights and data gathered from more than 150,000 robotic ablation procedures performed with predecessor catheters.
“We are thrilled to announce this significant milestone and introduce the MAGiC catheter to European physicians and patients,” said David Fischel, chairman and CEO of Stereotaxis.
“We want to thank and recognize the significant contributions from clinicians who guided us throughout the development efforts and team members of Stereotaxis and Osypka that made this possible. We look forward to seeing MAGiC serve as one of the key pillars in our effort to make robotics broadly impactful and beneficial in electrophysiology and endovascular surgery,” Mr. Fischel added.
